Universal reference book for medicines
Product name: DALFAZ® RETARD (DALFAZ® RETARD)

Active substance: alfuzosin

Type: A drug used for urination disorders associated with benign prostatic hyperplasia.
Alpha 1- adrenoblocker
Manufacturer: SANOFI WINTHROP INDUSTRIE (France)
Description of the active substance:
This information is a reference and it is not enough that the drug was prescribed by a doctor.
.
PHARMACHOLOGIC EFFECT
Alfa-adrenoblocker, acting mainly on postsynaptic?
1- adrenoreceptors. Blocking? 1- adrenoreceptors located in the triangle and sphincter of the bladder, urethra, alfuzosin eliminates spasm of smooth muscle fibers, which leads to a decrease in the resistance of urine outflow. Reduces the tone of the smooth muscles of the arteries and veins. Reduces OPSS and systemic blood pressure.
PHARMACOKINETICS
After ingestion, alfuzosin is absorbed from the digestive tract.
C max in blood plasma is achieved after 3 hours and is 10.3 ng / ml. Differences in maximum and minimum plasma concentrations are negligible. Eating does not affect suction.
Binding to plasma proteins is about 90%.
Metabolised in the liver. T 1/2 - 8 hours. 15-30% of inactive metabolites are excreted in the urine, 75-91% - with feces. 11% of alfuzosin is excreted unchanged in the urine.
Patients over 75 years of age have a higher plasma concentration and bioavailability of alfuzosin (possibly due to a decrease in metabolism in the liver).
In patients with severe renal dysfunction, an increase in alfuzosin clearance is possible (possibly due to less binding to plasma proteins).
INDICATIONS
Treatment of functional manifestations of benign prostatic hyperplasia in the absence of surgical intervention, as well as in cases of progressive growth, especially in elderly patients.

DOSING MODE
Inside - for 2.5 mg 3 times / day.
For patients older than 65 years - the initial dose is 2.5 mg 2 times / day (morning and evening); in the future, the dose may be increased (but not more than 10 mg / day).
SIDE EFFECT
From the digestive system: pain in epigastrium, nausea, diarrhea;
rarely dry mouth.
From the side of the central nervous system: dizziness, headache;
rarely - drowsiness.
From the cardiovascular system: rarely - tachycardia, orthostatic hypotension.

Allergic reactions: rarely - skin rash, itching.

Other: malaise;
rarely - swelling, pain behind the sternum.
CONTRAINDICATIONS
Instructions in anamnesis for orthostatic hypotension, simultaneous use of other alpha-blockers, increased sensitivity to alfuzosin.

PREGNANCY AND LACTATION
The drug is not intended for use in women.

APPLICATION FOR FUNCTIONS OF THE LIVER
Use with caution in patients with severe renal dysfunction.

APPLICATION FOR CHILDREN
The drug is not intended for use in children.

APPLICATION IN ELDERLY PATIENTS
For patients older than 65 years - the initial dose is 2.5 mg 2 times / day (morning and evening);
in the future, the dose may be increased (but not more than 10 mg / day).
Use with caution in patients older than 75 years.

SPECIAL INSTRUCTIONS
Use with caution in patients with IHD, angina pectoris.
If there is a worsening of the course of angina, alfuzosin should be discontinued.
Use with caution in patients older than 75 years and patients with severe renal dysfunction.

DRUG INTERACTION
With simultaneous use of alfuzosin with antihypertensive agents (especially calcium channel blockers), a marked decrease in blood pressure is possible, up to the development of collapse.

With the simultaneous use of alfuzosin with funds for general anesthesia, the development of instability of blood pressure during anesthesia is likely.

Incompatible with other alpha 1- adrenoblockers.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!